Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Wee Joo Chng

Wee Joo Chng

MB ChB, MRCP, MRCPath, PhD
National University of Singapore
Managing toxicities associated with bispecific T-cell engaging therapies in patients with myeloma 2:11
Managing toxicities associated with bispecific T-cell engaging therapies in patients with myeloma
Wee Joo Chng • 26 Sep 2024
Selecting a therapeutic approach for patients with relapsed/refractory myeloma 2:06
Selecting a therapeutic approach for patients with relapsed/refractory myeloma
Wee Joo Chng • 26 Sep 2024
Identifying high-risk myeloma: looking beyond cytogenetic factors 1:18
Identifying high-risk myeloma: looking beyond cytogenetic factors
Wee Joo Chng • 26 Sep 2024
Treatment options for patients with multiple myeloma refractory to lenalidomide 1:57
Treatment options for patients with multiple myeloma refractory to lenalidomide
Wee Joo Chng • 29 Sep 2023
Highlights of IMS 2023: the origins of myeloma and the role of the microenvironment 2:08
Highlights of IMS 2023: the origins of myeloma and the role of the microenvironment
Wee Joo Chng • 29 Sep 2023
Metabolic reprogramming confers resistance to lenalidomide in multiple myeloma 1:32
Metabolic reprogramming confers resistance to lenalidomide in multiple myeloma
Wee Joo Chng • 29 Sep 2023
Novel immunotherapies for multiple myeloma & other exciting developments 1:08
Novel immunotherapies for multiple myeloma & other exciting developments
Wee Joo Chng • 29 Sep 2023
IMS session highlights: high-risk myeloma 2:05
IMS session highlights: high-risk myeloma
Wee Joo Chng • 26 Sep 2022
The impact of metabolic vulnerabilities in multiple myeloma 1:23
The impact of metabolic vulnerabilities in multiple myeloma
Wee Joo Chng • 26 Aug 2022
The role of STAT3 signaling in multiple myeloma 1:58
The role of STAT3 signaling in multiple myeloma
Wee Joo Chng • 26 Aug 2022
Advances in myeloma genomics and tailored patient therapy 3:46
Advances in myeloma genomics and tailored patient therapy
Wee Joo Chng • 14 Sep 2019
The future prospects of adapting genomics to clinical practice 2:13
The future prospects of adapting genomics to clinical practice
Wee Joo Chng • 15 Sep 2019
Re-evaluating the role of epigenetics in multiple myeloma 12:00
Re-evaluating the role of epigenetics in multiple myeloma
Brian Walker et al. • 18 Oct 2017
How next-generation sequencing will change clinical practice 2:25
How next-generation sequencing will change clinical practice
Wee Joo Chng • 18 Apr 2016
The utility of next-generation sequencing for multiple myeloma 2:16
The utility of next-generation sequencing for multiple myeloma
Wee Joo Chng • 18 Apr 2016
Myeloma 2016: Panel discussion on the status of genomics 14:35
Myeloma 2016: Panel discussion on the status of genomics
Gareth Morgan et al. • 14 Jun 2016
The content of VJHemOnc is intended for healthcare professionals